Haemophilia as a blueprint for gene therapy

Exploring the impact on patients' lives and patient care

EHA 30th Annual Congress, June 9–12 2022 

Watch the full symposium video recording of the CSL Behring EHA satellite symposium held on June 9, 2022.

The symposium was co-chaired by Ingrid Pabinger (Austria) and Wolfgang Miesbach (Germany) and featured presentations from Wolfgang Miesbach, Greta Mulders (The Netherlands), Daan Breederveld (The Netherlands). The first half of the symposium highlighted the current gene therapy landscape in bleeding disorders and the status of gene therapies in clinical trials for haemophilia. The second half of the symposium considered the arrival of gene therapy from a 360° view of the physician, nurse and patient perspective.

The presentations were followed by an interactive discussion section with the faculty and audience.

This information was developed for an EU audience. Please note that this webinar contains information on specific products and indications, including discussion of products in late-stage clinical trials which are not currently licenced. The Summary of Product Characteristics (SmPC) provided may vary depending on local approval in each country. Best efforts were undertaken by CSL Behring and congress sponsors to ensure compliance with EFPIA Code of Practice in line with the Joint Guidelines (IFPMA, EFPIA and PhRMA). However, you should review your local prescribing information and/or SmPC and consult directly with the local affiliate of CSL Behring to address any questions.